JPRN-UMIN000020299
Completed
未知
A Study on Predictors of Treatment Response to ombitasvir/paritaprevir/r combination therapy in Patients with genotype 1 Chronic Hepatitis C Virus Infection - Predictor of treatment response to Ombitasvir /Paritaprevir/r therapy
ConditionsPatients with genotype 1 HCV infection
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients with genotype 1 HCV infection
- Sponsor
- Hokkaido University
- Enrollment
- 260
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients with poorly controlled cardiac disease (e.g., myocardial infarction, cardiac failure, arrhythmia) 2\)Patients with severe hepatic impairment 3\)Patients with a history of hypersensitivity to HCV protease inhibitors or NS5A inhibitor 4\)Patients with a concurrent malignancy, including hepatocellular carcinoma, at the start of treatment 5\)Patients deemed unsuitable for study entry by their treating physician 6\)Patients who are unsuitable, in the opinion of the principal investigator, for this study due to any other reason
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Study on Predictors of Treatment Response to Sofosbuvir and Ribavirin Therapy in Patients with genotype 2 Chronic Hepatitis C Virus InfectioPatients with genotype 2 HCV infectionJPRN-UMIN000018947Hokkaido University Department of Gastroenterology and Hepatology, Graduate School of Medicine,260
Completed
Not Applicable
A Study on Predictors of Treatment Response to Sofosbuvir and Ledipasvir Therapy in Patients with genotype 1 Chronic Hepatitis C Virus InfectioPatients with genotype 1 HCV infectionJPRN-UMIN000019011Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University260
Recruiting
Phase 4
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-label, controlled, randomized multinational pragmatic trial.2024-516783-29-00Cliniques Universitaires Saint-Luc340
Active, not recruiting
Phase 1
Predictive factors of response to omalizumab and mepolizumab in asthma.Adult patients (18-90 years old) with severe asthma and eligible for both XOLAIR and NUCALA therapies, and agreeing on participating (signature of a written informed consent).Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-002473-19-FRCliniques Universitaires Saint-Luc364
Recruiting
Not Applicable
A prospective study of treatment response of patients with myelofibrosis and PNH type blood cellsmyelofibrosisJPRN-UMIN000045859Juntendo University100